Advocacy intelligence hub — real-time data for patient organizations
IRCCS Burlo Garofolo — NA
HUMIRA: FDA approved
Treatment of moderate to severe hidradenitis suppurativa
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
HUMIRA
(adalimumab)Orphan drugAbbVie, Inc.
12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalim...
Browse all NON RARE IN EUROPE: Hidradenitis suppurativa news →
View all NON RARE IN EUROPE: Hidradenitis suppurativa specialists →